AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

May 08, 2018

AbbVie to Present at the UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 22, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7:30 a.m. Central time.

May 02, 2018

AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference

NORTH CHICAGO, Ill., May 2, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 2018 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018. Richard A. Gonzalez, chairman and chief executive officer, will present at 6:20 p.m. Central time.

May 01, 2018

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

NORTH CHICAGO, Ill., May 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.

May 01, 2018

AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock

NORTH CHICAGO, Ill., May 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has commenced a modified "Dutch auction" tender offer to purchase for cash up to $7.5 billion of its common stock at a price not less than $99.00 per share and not more than $114.00 per share.

Apr 30, 2018

AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology

NORTH CHICAGO, Ill. and HOUSTON, April 30, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, and Rice University today announced they have entered into a joint research collaboration to establish the K.C. Nicolaou Research Accelerator. The research at the Accelerator will focus on synthesizing novel cytotoxic agents for use in the fight against cancer. The collaboration will complement AbbVie's existing expertise in oncology discovery and early development.

Apr 27, 2018

AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

NORTH CHICAGO, Ill., April 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data  for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, TX.

Apr 26, 2018

AbbVie Reports First-Quarter 2018 Financial Results

NORTH CHICAGO, Ill., April 26, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2018.
Apr 25, 2018

AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

NORTH CHICAGO, Ill., April 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for treatment of patients with moderate to severe plaque psoriasis.

Apr 25, 2018

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

NORTH CHICAGO, Ill., April 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2b/3 SELECT-SUNRISE clinical trial, showing that at 12 weeks, all doses of upadacitinib (7.5 mg, 15 mg and 30 mg, once-daily) met the study's primary endpoint of ACR20a versus placebo.1 Certain key efficacy endpoints were also achieved versus placebo.1 The study, conducted in Japan, evaluates upadacitinib, an investigational oral JAK1-selective inhibitor, in adult Japanese patients with moderate to severe rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and have had an inadequate response to csDMARDs.1 These data will be presented during an oral presentation at the Japan College of Rheumatology (JCR) 2018 Annual Scientific Meeting in Tokyo on Saturday, April 28, 2018. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

Apr 18, 2018

AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference

NORTH CHICAGO, Ill., April 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43rd Annual Health Care Conference on Wednesday, May 9, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7 a.m. Central time.